Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment

Author(s): Emilio Francesco Giunta , Giuseppe Argenziano , Gabriella Brancaccio , Erika Martinelli , Fortunato Ciardiello , Teresa Troiani* .

Journal Name: Current Cancer Therapy Reviews

Volume 15 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Metastatic melanoma treatment has dramatically changed in the last few years, having a breakthrough with the introduction of targeted agents and immunotherapy. PD-1/PD-L1 pathway is one of the physiologic mechanisms of peripheral immune tolerance, but it also represents a mechanism of tumor immune escape. PD-1/PD-L1 inhibitors represent new immune-checkpoint drugs currently used in metastatic melanoma treatment.

Resistance to PD-1/PD-L1 axis blockade, which is the main cause of therapeutic failure during therapeutic use of these drugs, could be linked to several mechanism of immune escape. In fact, other inhibitory receptor such as CTLA-4, LAG-3, TIM-3 and TIGIT might be co-expressed on T cells, deleting the effect of anti-PD-1/PD-L1; overexpression of the enzyme IDO could cause immunosuppression through the depletion of tryptophan in the tumor microenvironment; defective c ostimulation (through reduced activity of 4-1BB and OX40 receptors) could result in T-cell energy.

Combination of anti-PD-1/PD-L1 with drugs targeting inhibitory or costimulatory receptors, intracellular pathways, enzymes or neoangiogenesis could be a possible strategy to overcome resistance to single PD-1/PD-L1 blockade. Clinical trials evaluating combination therapies have already showed interesting results, although most of them are still on going.

Keywords: Metastatic melanoma, immunotherapy, immune-checkpoint, PD-1, PD-L1, immune tolerance.

[1]
Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40: 1825-36.
[2]
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10: 85.
[3]
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines. Ann Oncol 2015; 26(Suppl. 5): V126-32.
[4]
Raaijmakers MI, Rozati S, Goldinger SM. Melanoma immunotherapy: Historical precedents, recent successes and future prospects. Immunotherapy 2013; 5(2): 169-82.
[5]
Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J 2000; 6(Suppl. 1): S11-4.
[6]
Mocellin S, Lens MB, Pasquali S, Pilati P. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 18(6)CD008955
[7]
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
[8]
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-95.
[9]
Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229: 114-25.
[10]
Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol 2014; 290(1): 72-9.
[11]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
[12]
Dyck L, Wilk MM, Raverdeau M. Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol Immunother 2016; 65(12): 1491-8.
[13]
Fry AM, Lanier LL, Weiss A. Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. J Exp Med 1996; 184: 295-300.
[14]
Lorenz U. SHP-1 and SHP-2 in T cells: Two phosphatases functioning at many levels. Immunol Rev 2009; 228: 342-59.
[15]
Muenst S, Soyal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 2015; 19(2): 201-11.
[16]
Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015; 75(3): 508-18.
[17]
Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
[18]
Ishiwata K, Watanabe N, Guo M, et al. Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis. J Immunol 2010; 184(4): 2086-94.
[19]
Sznol M, Chen LP. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19(5): 1021-34.
[20]
Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27(1): 111-22.
[21]
Weber Jeffrey S. Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-84.
[22]
Robert C, Long GV, Brady B, Dutriaux C. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
[23]
Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
[24]
Robert C, Schachter J, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
[25]
Genentech, Inc. A phase 1b study of atezolizumab in combination with vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive metastatic melanoma. Clinical- Trials.gov Identifier: NCT01656642, 2012.
[26]
Hodi FS, Kluger HM, Sullivan RJ, et al. Clinical activity of the PD-L1 inhibitor MPDL3280A in patients with metastatic melanoma: Updated phase I data. In Society for Melanoma Research 2014 Congress. Pigment Cell Melanoma Res 2014; 27: 1169-98.
[27]
Genentech, Inc. Phase 1 Safety and tolerability of MEDI4736 in combination with dabrafenib and trametinib or with trametinib alone. ClinicalTrials.gov Identifier: NCT02027961, 2014.
[28]
Genentech, Inc. A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO-203) ClinicalTrials.gov Identifier: NCT02318277, 2014.
[29]
Riella LV, Paterson AM. Role of the PD-1 pathway in the immune response. Am J Transplant 2012; 12(10): 2575-87.
[30]
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4127ra37
[31]
Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol 2016; 28(8): 383-91.
[32]
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39: 1-10.
[33]
Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015; 11: 1018.
[34]
Martinez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 2015; 21: 5047-56.
[35]
Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232(2): 199-209.
[36]
Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5200ra116
[37]
Hwang SL, Chung NP, Chan JK, Lin CL. Indoleamine 2,3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res 2005; 15: 167-75.
[38]
Soliman H. Indoleamine 2,3-dioxygenase: Is it an immune suppressor? Cancer J 2010; 16(4): 354-9.
[39]
Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353.
[40]
Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177: 4376.
[41]
Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70: 7788-99.
[42]
Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol 2003; 195(3): 346-55.
[43]
Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-37.
[44]
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann Oncol 2016; 27: 1492-504.
[45]
Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99.
[46]
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
[47]
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol 2013; 13: 227-42.
[48]
Shindo Y, Yoshimura K, Kuramasu A, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res 2015; 35: 129-36.
[49]
Guo Z, Wang X, Cheng D, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014; 9e89350
[50]
Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015; 6: 7458.
[51]
Proost P, Mortier A, Loos T, et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007; 110: 37-44.
[52]
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-80.
[53]
Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-53.
[54]
Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-8.
[55]
Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-10.
[56]
Walker LS, Sansom DM. The emerging role of CTLA-4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852-63.
[57]
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
[58]
Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17(11): 1558-68.
[59]
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-76.
[60]
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-9.
[61]
Bartkowiak T, Curran MA. 4-1BB agonists: Multi-potent potentiators of tumor immunity. Front Oncol 2015; 5: 117.
[62]
Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: Complexities and challenges. Immunol Rev 2009; 229(1): 192-215.
[63]
Ju SA, Lee SC, Kwon TH. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005; 83(4): 344-51.
[64]
Squibb BM. Study of BMS-663513 in Patients with advanced cancer. ClinicalTrials.gov Identifier: NCT00309023, 2006.
[65]
Squibb BM. Phase II, 2nd Line Melanoma - RAND Monotherapy. ClinicalTrials.gov Identifier: NCT00612664 2008.
[66]
Squibb BM. Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma. ClinicalTrialsgov Identifier: NCT00803374, 2006.
[67]
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14(8): 561-84.
[68]
Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer 2014; 2: 7.
[69]
Medlmmune LCC. A phase 1b/2 safety and tolerability of MEDI6469 in combination with therapeutic immune agents or monoclonal antibodies (MEDI6469). ClinicalTrials.gov Identifier: NCT02205333 2013.
[70]
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990; 171(5): 1393-405.
[71]
Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994; 39(3): 213-7.
[72]
Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005; 115(2): 170-8.
[73]
Woo SR, Turnis ME, Goldberg MV. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res 2012; 72(4): 917-27.
[74]
Squibb BM. Safety study of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors. ClinicalTrialsgov Identifier: NCT01968109, 2013.
[75]
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10(1): 48-57.
[76]
Li M, Xia P, Du Y, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem 2014; 289: 17647-57.
[77]
Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 2015; 125(5): 2046-58.
[78]
McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001; 2: 1109-16.
[79]
Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-41.
[80]
Anderson AC. Tim-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2014; 2(5): 393-8.
[81]
Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-52.
[82]
Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
[83]
Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-94.
[84]
Tesaro. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors. ClinicalTrials.gov Identifier: NCT02817633, 2106.
[85]
Novartics Pharmaceuticals. Safety and efficacy of MBG453 as single agent and in combination with PDR001 in patients with advanced malignancies. ClinicalTrials.gov Identifier: NCT02608268 2015.
[86]
Munn DH. Blocking IDO activity to enhance antitumor immunity. Front Biosci (Elite Ed) 2012; 4: 734-45.
[87]
Beatty GL, O’Dwyer PJ, Clark J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 2013; 31: 3025.
[88]
Fred Hutchinson Cancer Research Center.Epacadostat and vaccine therapy in treating patients with stage IIIIV melanoma.ClinicalTrials. gov Identifier: NCT01961115 2013.
[89]
Incyte Corporation. A phase 1/2 randomized, blinded, placebo controlled study of ipilimumab in combination with INCB024360 or placebo in subjects with unresectable or metastatic melanoma. ClinicalTrials.gov Identifier: NCT01604889, 2012.
[90]
Merck Sharp & Dohme Corp. Study of INCB024360 alone and in combination with pembrolizumab (MK-3475) in solid tumors (MK-3475-434) (KEYNOTE-434) ClinicalTrials.gov Identifier: NCT02862457, 2016.
[91]
Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159(1): 223-35.
[92]
Schuster C, Eikesdal HP, Puntervoll H, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: Predictive importance of induced early hypertension. PLoS One 2012; 7(6)e38364
[93]
Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30(1): 34-41.
[94]
Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775. Cancer 2013; 119(3): 586-92.
[95]
Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. OncoImmunology 2013; 2e24436
[96]
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2(7): 632-42.
[97]
Ipilimumab with or without bevacizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. ClinicalTrials. gov Identifier: NCT01950390
[98]
Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015; 5: 202.
[99]
McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773(8): 1263-84.
[100]
Stewart R, Poon E, Mullins S, Watkins A. Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo. J Immunother Cancer 2014; 2(Suppl. 3): 128.
[101]
Irving BA, Cheung J, Yang Y, Moskalenka M. MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction. J Immunother Cancer 2013; 1(Suppl. 1): 79.
[102]
Hoffmann-La Roche. Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors.ClinicalTrials.gov Identifier: NCT01988896, 2013.
[103]
Hoffmann-La Roche.A study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAFV600 mutation-positive participants with metastatic or unresectable locally advanced melanoma.ClinicalTrials. gov Identifier: NCT02908672, 2016.
[104]
Hoffmann-La Roche A study to investigate efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy versus regorafenib in participants with metastatic colorectal adenocarcinoma.ClinicalTrials.gov Identifier: NCT02788279, 2016.
[105]
Hoffmann-La Roche. A study of the safety and efficacy of pembrolizumab (mk-3475) in combination with trametinib and dabrafenib in participants with advanced melanoma (MK-3475- 022/KEYNOTE-022). ClinicalTrials.gov Identifier: NCT02130466 2016.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 2
Year: 2019
Page: [110 - 119]
Pages: 10
DOI: 10.2174/1573394714666180927095650
Price: $58

Article Metrics

PDF: 35
HTML: 2
PRC: 1